Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

A cleavable signal peptide controls the topology and Golgi targeting of the membrane protein TMEM165

Created on 21 Aug 2026

Authors

Velings, M.-O., Simar, R., Bleret, A., Tevel, V., Boonen, M., Morsomme, P.

Abstract

TMEM165 is a Golgi-resident multi-pass membrane protein involved in divalent cation homeostasis and associated with congenital disorders of glycosylation, yet its N-terminal biogenesis has remained unresolved. Here, we demonstrate that TMEM165 contains a functional cleavable signal peptide required for correct Golgi targeting and membrane topology. Loss of this signal peptide causes protein mislocalization, and altered topology with N-terminal cytosolic exposure, whereas extended N-terminal deletion restores both Golgi localization and overall membrane topology, consistent with insertion mediated by the first transmembrane domain as commonly described for multi-pass membrane proteins. Importantly, this N-terminally truncated form remains responsive to manganese-induced degradation and partially restores glycosylation defects associated with TMEM165 deficiency, indicating that the extended N-terminal region is dispensable for core TMEM165 function. Together, these findings identify the signal peptide as a key determinant of TMEM165 biogenesis and suggest that its conservation may contribute not only to membrane targeting, but also to maintaining the proper luminal environment of the N-terminus during early biogenesis.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 21 Aug 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement